Innovotech Inc
Innovotech Inc. provides assay kits used in growing microbial biofilms for research purposes in Canada, the United States, and internationally. The company offers InnovoSIL, a silver periodate antimicrobial compounds for medical applications; and MBEC Assay kit, a screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms; pre-coated MBEC Assa… Read more
Innovotech Inc (IOT) - Net Assets
Latest net assets as of September 2025: CA$2.80 Million CAD
Based on the latest financial reports, Innovotech Inc (IOT) has net assets worth CA$2.80 Million CAD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$3.39 Million) and total liabilities (CA$585.33K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$2.80 Million |
| % of Total Assets | 82.72% |
| Annual Growth Rate | 5.5% |
| 5-Year Change | 306.7% |
| 10-Year Change | N/A |
| Growth Volatility | 193.84 |
Innovotech Inc - Net Assets Trend (2003–2024)
This chart illustrates how Innovotech Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Innovotech Inc (2003–2024)
The table below shows the annual net assets of Innovotech Inc from 2003 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CA$2.62 Million | +162.68% |
| 2023-12-31 | CA$998.60K | -5.57% |
| 2022-12-31 | CA$1.06 Million | -10.15% |
| 2021-12-31 | CA$1.18 Million | +82.48% |
| 2020-12-31 | CA$644.98K | +557.56% |
| 2019-12-31 | CA$98.09K | +4.94% |
| 2018-12-31 | CA$93.47K | -48.50% |
| 2017-12-31 | CA$181.51K | +114.90% |
| 2016-12-31 | CA$-1.22 Million | -21.49% |
| 2015-12-31 | CA$-1.00 Million | -30.99% |
| 2014-12-31 | CA$-765.66K | -34.48% |
| 2013-12-31 | CA$-569.33K | -168.03% |
| 2003-12-31 | CA$836.94K | -0.53% |
| 2003-09-30 | CA$841.40K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Innovotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 831236300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$10.89 Million | 424.54% |
| Total Equity | CA$2.57 Million | 100.00% |
Innovotech Inc Competitors by Market Cap
The table below lists competitors of Innovotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tambourah Metals Ltd
AU:TMB
|
$4.32 Million |
|
Civil Engineering PCL
BK:CIVIL
|
$4.32 Million |
|
Masivo Silver Corp
PINK:GNYPF
|
$4.33 Million |
|
Krynica Vitamin SA
WAR:KVT
|
$4.33 Million |
|
Gelteq Limited Ordinary Shares
NASDAQ:GELS
|
$4.32 Million |
|
Bri-Chem Corp
OTCQB:BRYFF
|
$4.32 Million |
|
FenixOro Gold Corp
PINK:FDVXF
|
$4.31 Million |
|
The Tinley Beverage Company Inc
OTCQB:TNYBF
|
$4.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Innovotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 930,599 to 2,565,111, a change of 1,634,512 (175.6%).
- Net income of 224,735 contributed positively to equity growth.
- New share issuances of 1,129,042 increased equity.
- Other factors increased equity by 280,735.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$224.74K | +8.76% |
| Share Issuances | CA$1.13 Million | +44.02% |
| Other Changes | CA$280.74K | +10.94% |
| Total Change | CA$- | 175.64% |
Book Value vs Market Value Analysis
This analysis compares Innovotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.07x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 39.04x to 4.07x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CA$0.01 | CA$0.21 | x |
| 2018-12-31 | CA$0.00 | CA$0.21 | x |
| 2019-12-31 | CA$0.00 | CA$0.21 | x |
| 2020-12-31 | CA$0.02 | CA$0.21 | x |
| 2021-12-31 | CA$0.03 | CA$0.21 | x |
| 2022-12-31 | CA$0.03 | CA$0.21 | x |
| 2023-12-31 | CA$0.02 | CA$0.21 | x |
| 2024-12-31 | CA$0.05 | CA$0.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Innovotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.76%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.24%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 1.26x
- Recent ROE (8.76%) is below the historical average (18.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | -1.62% | 0.00% | 0.00x | 1.05x | CA$-97.77K |
| 2003 | -1.74% | 0.00% | 0.00x | 1.00x | CA$-98.22K |
| 2013 | 0.00% | -93.07% | 2.10x | 0.00x | CA$-770.32K |
| 2014 | 0.00% | -23.23% | 2.21x | 0.00x | CA$-133.07K |
| 2015 | 0.00% | -35.41% | 3.32x | 0.00x | CA$-150.31K |
| 2016 | 0.00% | -21.43% | 3.09x | 0.00x | CA$-93.69K |
| 2017 | 415.07% | 76.07% | 1.88x | 2.90x | CA$735.23K |
| 2018 | -136.55% | -15.43% | 3.04x | 2.91x | CA$-136.98K |
| 2019 | -49.71% | -4.94% | 3.59x | 2.80x | CA$-58.57K |
| 2020 | 16.48% | 8.91% | 1.45x | 1.28x | CA$41.82K |
| 2021 | 31.19% | 24.78% | 1.03x | 1.22x | CA$249.44K |
| 2022 | -12.91% | -12.13% | 0.92x | 1.16x | CA$-242.26K |
| 2023 | -16.93% | -13.32% | 0.97x | 1.31x | CA$-250.64K |
| 2024 | 8.76% | 10.24% | 0.68x | 1.26x | CA$-31.78K |
Industry Comparison
This section compares Innovotech Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,141,701
- Average return on equity (ROE) among peers: -80.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Innovotech Inc (IOT) | CA$2.80 Million | -1.62% | 0.21x | $4.32 Million |
| Rakovina Therapeutics Inc (RKV) | $4.30 Million | -94.74% | 0.45x | $1.14 Million |
| Thiogenesis Therapeutics Corp. (TTI) | $83.35K | -111.19% | 0.76x | $14.25 Million |
| Waverley Pharma Inc (WAVE) | $2.04 Million | -34.55% | 0.71x | $235.88K |